Stanford Pathology in the News

Stanford Molecular Pathology Laboratory designated
as NCI-MATCH testing Laboratory

March 15, 2019

Dear Colleagues,

I am proud to inform you that the Stanford Molecular Pathology Lab has been approved by the National Cancer Institute as a designated NCI-MATCH testing laboratory. This means that Stanford patients who wish to participate in the NCI-MATCH clinical trial now can do so based on the results of our STAMP (Stanford Actionable Mutation Panel) assay without the need for additional testing. This is a great improvement for our patients and a welcome recognition of the quality and value of our in-house NGS testing. With this designation we now join a network of select academic institutions and molecular testing companies that can identify patients for the NCI-MATCH trial. I wish to thank Dr. Henning Stehr, Assistant Professor of Pathology for leading this effort, and the entire Molecular Pathology team for this great accomplishment. Their efforts are bringing state of the art NGS testing to Stanford in support of personalized cancer care with the STAMP (solid tumor), Heme-STAMP (myeloid and lymphoid tumors) and Fusion- STAMP (RNA-based fusion detection, available April 1 2019) panels. Please join me in congratulating Henning and the Molecular Pathology team.

Sincerely,

Thomas Montine, MD, PhD
Stanford Medicine Endowed Professor in Pathology Chair,
Chair, Department of Pathology
Director, Pacific Udall Center

For more information on these tests:

Email:
match-testing@stanford.edu

Web:
ECog-Acrin Cancer Research Group: NCI-MATCH / EAY131 Genomic Testing
Stanford Lab: Solid Tumor Actionable Mutation Panel
Stanford Lab: HEME-STAMP